Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J.
Chavez JC, et al.
Leuk Res. 2016 Aug;47:78-83. doi: 10.1016/j.leukres.2016.05.012. Epub 2016 May 17.
Leuk Res. 2016.
PMID: 27285853
Clinical Trial.